- Home
- AXL vs EYPT Comparison
AXL vs EYPT Comparison
Compare AXL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXL
- EYPT
- Stock Information
- Founded
- AXL 1994
- EYPT 1987
- Country
- AXL United States
- EYPT United States
- Employees
- AXL N/A
- EYPT N/A
- Industry
- AXL Auto Parts:O.E.M.
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- AXL Consumer Discretionary
- EYPT Industrials
- Exchange
- AXL Nasdaq
- EYPT Nasdaq
- Market Cap
- AXL 739.6M
- EYPT 594.5M
- IPO Year
- AXL 1999
- EYPT 2005
- Fundamental
- Price
- AXL $5.99
- EYPT $7.44
- Analyst Decision
- AXL Hold
- EYPT Strong Buy
- Analyst Count
- AXL 4
- EYPT 8
- Target Price
- AXL $7.38
- EYPT $27.29
- AVG Volume (30 Days)
- AXL 1.3M
- EYPT 898.1K
- Earning Date
- AXL 02-14-2025
- EYPT 11-07-2024
- Dividend Yield
- AXL N/A
- EYPT N/A
- EPS Growth
- AXL N/A
- EYPT N/A
- EPS
- AXL 0.23
- EYPT N/A
- Revenue
- AXL $6,207,100,000.00
- EYPT $45,713,000.00
- Revenue This Year
- AXL $1.78
- EYPT N/A
- Revenue Next Year
- AXL N/A
- EYPT N/A
- P/E Ratio
- AXL $25.81
- EYPT N/A
- Revenue Growth
- AXL 3.29
- EYPT 7.50
- 52 Week Low
- AXL $5.43
- EYPT $7.21
- 52 Week High
- AXL $8.99
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- AXL 36.16
- EYPT 36.37
- Support Level
- AXL $6.73
- EYPT $7.21
- Resistance Level
- AXL $6.90
- EYPT $8.21
- Average True Range (ATR)
- AXL 0.23
- EYPT 0.54
- MACD
- AXL -0.09
- EYPT -0.06
- Stochastic Oscillator
- AXL 7.52
- EYPT 11.39
About AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.